Comparison 2.

Overview adverse events for AZ or AZ combinations vs. control for P. falciparum

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Treatment related adverse events	5		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 AZ vs. CQ	1	32	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.46, 1.71]
1.2 AZCQ vs. CQ	1	79	Risk Ratio (M‐H, Fixed, 95% CI)	0.37 [0.19, 0.70]
1.3 AZCQ vs. AZ monotherapy	1	79	Risk Ratio (M‐H, Fixed, 95% CI)	0.41 [0.21, 0.82]
1.4 AZCQ vs. SPCQ	1	25	Risk Ratio (M‐H, Fixed, 95% CI)	1.48 [0.67, 3.27]
1.5 AZCQ vs. MQ	2	458	Risk Ratio (M‐H, Fixed, 95% CI)	1.20 [1.06, 1.36]
1.6 AZ‐artesunate vs. AZ‐quinine (arm 1 vs. 4)	1	54	Risk Ratio (M‐H, Fixed, 95% CI)	0.05 [0.01, 0.37]
2 All adverse events (any cause)	6		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 AZCQ vs. SPCQ	1	25	Risk Ratio (M‐H, Fixed, 95% CI)	1.32 [0.75, 2.32]
2.2 AZCQ vs. atovaquone‐proguanil	1	230	Risk Ratio (M‐H, Fixed, 95% CI)	1.41 [1.09, 1.83]
2.3 AZCQ vs. MQ	2	458	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.96, 1.10]
2.4 AZ‐artemether vs. doxycycline‐artemether	1	57	Risk Ratio (M‐H, Fixed, 95% CI)	0.28 [0.09, 0.88]
2.5 AZ‐artesunate vs. artemether‐lumefantrine	1	261	Risk Ratio (M‐H, Fixed, 95% CI)	1.21 [0.81, 1.80]